Revolutionary, biofluid-based diagnostics to deliver personalized precision healthcare
Exosome is a diagnostics company that started to commercialize its proprietary minimally-invasive, body fluid-based molecular diagnostics platform for use in companion diagnostic applications and real-time monitoring of actionable cancer markers. Its lead product the ExoDx®Prostate(IntelliScore) is a non-invasive urine-based test designed to predict high-grade prostate cancer and avoid an initial unnecessary biopsy. In addition the company closed several CDx collaborations with pharma.
- CEO John Boyce
- Industry Diagnostics
- History M&A